Asia Pacific Bladder Cancer Diagnostics Market Overview
According to SPER Market Research, the Asia Pacific Bladder Cancer Diagnostics Market is estimated to reach USD XX billion by 2033 with a CAGR XX%.
The onset of bladder cancer occurs when normal cells in the lining of the bladder, primarily urothelial cells, undergo a transformation and uncontrolled growth, resulting in the formation of a mass known as a tumor. Urothelial cells also line the renal pelvis, ureters, and urethra. Consequently, cancer originating in the renal pelvis and ureters is categorized as a form of urothelial cancer, often referred to as upper tract urothelial cancer. Generally, this type of cancer is treated similarly to bladder cancer, as described in this guide. Tumors can be classified as either cancerous or benign. A cancerous tumour is considered malignant, as it has the ability to grow and spread to other parts of the body. Conversely, a benign tumour can grow but not advance. It is important to note that benign bladder tumors are exceedingly uncommon.
Exploring the Growth Drivers of the Asia Pacific Bladder Cancer Diagnostics Industry
The global incidence of bladder cancer is increasing, with most gene mutations associated with the disease occurring during a person's lifetime rather than being inherited. Exposure to cancer-causing chemicals or radiation, such as those found in tobacco smoke, can contribute to these acquired gene mutations. However, some gene changes may happen randomly within cells. Bladder cancer is predominantly seen in older individuals, with around 90% of cases occurring in people over 55 years old. The growing number of bladder cancer cases has led to an increased demand for bladder cancer diagnostic products, driving the growth of the Asia Pacific bladder cancer diagnostics market. Awareness of bladder cancer and the importance of early diagnosis are emphasized during the nationally recognized Bladder Cancer Awareness Month in the U.S. in May. Despite being less common than other cancers, bladder cancer affects over 720,000 patients in the U.S. Efforts are being made to advance research, patient care, education, and the development of innovative treatments for bladder tumour patients, particularly in the Asia-Pacific region, amid the ongoing COVID-19 crisis. The rising awareness of early bladder cancer diagnosis plays a significant role in propelling the Asia Pacific bladder cancer diagnostic market expansion.
What challenges does the Asia Pacific Bladder Cancer Diagnostics Market face?
Chemotherapy is a cancer treatment that uses drugs administered through the veins or orally to reach cancer cells throughout the body. However, some chemotherapy drugs cannot effectively enter the bladder to treat bladder cancer. Intravesical immunotherapy, such as Bacillus Calmette-Guerin (BCG), is commonly used for early-stage bladder cancer. BCG, a harmless bacterium related to the one causing tuberculosis, activates immune system cells in the bladder, prompting them to attack cancer cells. Chemotherapy drugs can have various side effects, including hair loss, mouth sores, nausea, fatigue, and increased infection risk. Certain drugs may cause kidney damage and hearing loss. These side effects may limit the growth of the Asia-Pacific bladder cancer diagnostics market.
In what ways has the COVID-19 pandemic affected Asia Pacific Bladder Cancer Diagnostics Market?
The Asia-Pacific bladder cancer diagnostics market has been negatively affected by the COVID-19 pandemic due to lockdown restrictions, resulting in reduced hospital visits and treatment delays. However, government support, advancements in imaging techniques, and increased collaborations among market players present opportunities for market growth. Despite the initial impact of the pandemic, the market has shown significant growth since reopening, and further expansion is expected. Market players are actively engaged in improving imaging techniques for early bladder cancer detection, bringing advancements and innovation to the market.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Test Type, By Stages, By Cancer Type, By End User, By Distribution Channel
|
| Regions covered | Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Thailand, Rest of Asia Pacific
|
| Companies Covered | Abbott, Agilent Technologies Inc., Ambu A/S, Bio-Rad Laboratories Inc., Canon Medical Systems Corporation, Cepheid, F. Hoffmann-La Roche Ltd, Fujifilm Corporation, General Electric Company, Hologic Inc., Illumina Inc., Koninklijke Philips N.V., Merck KGaA, MinFound Medical Systems Co, Neusoft Corporation, QIAGEN, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Time Medical Holding, Others
|
Key Target Audience:
- Healthcare Insurance Providers
- Healthcare IT and Software Providers
- Healthcare Providers
- Medical Device Manufacturers
- Patient Advocacy Groups
- Pharmaceutical and Biotechnology Companies
Asia Pacific Bladder Cancer Diagnostics Market Segmentation:
1. By Test Type:
- Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Test Type, 2023-2033
- Biopsy
- Cystoscopy
- Imaging test
- Urine lab test
- Others
2. By Stages:
- Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Stages, 2023-2033
- Stage I
- Stage II
- Stage III
- Stage IV
3. By Cancer Type:
- Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Cancer Type, 2023-2033
- Squamous Cell Bladder Cancer
- Transitional Cell Bladder Cancer
- Other Cancer Types
4. By End User:
- Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By End User, 2023-2033
- Associated Labs
- Cancer Research Institutes
- Diagnostic Imaging Centers
- Hospital
- Independent Diagnostic Laboratories
5. By Region:
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Thailand
- Rest of Asia Pacific
Key Topics Covered in the Report:
- Asia Pacific Bladder Cancer Diagnostics Market Size (FY’2023-FY’2033)
- Overview of Asia Pacific Bladder Cancer Diagnostics Market
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By Test Type (Biopsy, Cystoscopy, Imaging test, Urine lab test, Others)
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By Stages (Stage I, Stage II, Stage III, Stage IV)
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By Cancer Type (Squamous Cell Bladder Cancer, Transitional Cell Bladder Cancer, Other Cancer Types)
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By End User (Associated Labs, Cancer Research Institutes, Diagnostic Imaging Centers, Hospital, Independent Diagnostic Laboratories)
- Segmentation of Asia Pacific Bladder Cancer Diagnostics Market By Distribution Channel (Direct Tender, Retail Sales)
- Statistical Snap of Asia Pacific Bladder Cancer Diagnostics Market
- Growth Analysis of Asia Pacific Bladder Cancer Diagnostics Market
- Problems and Challenges in Asia Pacific Bladder Cancer Diagnostics Market
- Competitive Landscape in the Asia Pacific Bladder Cancer Diagnostics Market
- Impact of COVID-19 and Demonetization on Asia Pacific Bladder Cancer Diagnostics Market
- Details on Recent Investment in Asia Pacific Bladder Cancer Diagnostics Market
- Competitive Analysis of Asia Pacific Bladder Cancer Diagnostics Market
- Key Players in the Asia Pacific Bladder Cancer Diagnostics Market
- SWOT Analysis of Asia Pacific Bladder Cancer Diagnostics Market
- Asia Pacific Bladder Cancer Diagnostics Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Asia Pacific Bladder Cancer Diagnostics Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Asia Pacific Bladder Cancer Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Asia Pacific Bladder Cancer Diagnostics Market
7. Asia Pacific Bladder Cancer Diagnostics Market, By Test Type (USD Million)
7.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Test Type, 2023-2033
7.2. Biopsy
7.3. Cystoscopy
7.4. Imaging test
7.5. Urine lab test
7.6. Others
8. Asia Pacific Bladder Cancer Diagnostics Market, By Stages (USD Million)
8.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Stages, 2023-2033
8.2. Stage I
8.3. Stage II
8.4. Stage III
8.5. Stage IV
9. Asia Pacific Bladder Cancer Diagnostics Market, By Cancer Type (USD Million)
9.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Cancer Type, 2023-2033
9.2. Squamous Cell Bladder Cancer
9.3. Transitional Cell Bladder Cancer
9.4. Other Cancer Types
10. Asia Pacific Bladder Cancer Diagnostics Market, By End User (USD Million)
10.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By End User, 2023-2033
10.2. Associated Labs
10.3. Cancer Research Institutes
10.4. Diagnostic Imaging Centers
10.5. Hospital
10.6. Independent Diagnostic Laboratories
11. Asia Pacific Bladder Cancer Diagnostics Market, By Distribution Channel (USD Million)
11.1. Asia Pacific Bladder Cancer Diagnostics Market Value Share and Forecast, By Distribution Channel, 2023-2033
11.2. Direct Tender
11.3. Retail Sales
12. Asia Pacific Bladder Cancer Diagnostics Market Forecast, 2019-2033 (USD Million)
12.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share
13. Asia Pacific Bladder Cancer Diagnostics Market, By Test Type, 2019-2033 (USD Million)
13.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Test Type (2019-2026)
13.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Test Type (2027-2033)
14. Asia Pacific Bladder Cancer Diagnostics Market, By Stages, 2019-2033 (USD Million)
14.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Stages (2019-2026)
14.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Stages (2027-2033)
15. Asia Pacific Bladder Cancer Diagnostics Market, By Cancer Type, 2019-2033 (USD Million)
15.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Cancer Type (2019-2026)
15.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Cancer Type (2027-2033)
16. Asia Pacific Bladder Cancer Diagnostics Market, By End User, 2019-2033 (USD Million)
16.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by End User (2019-2026)
16.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by End User (2027-2033)
17. Asia Pacific Bladder Cancer Diagnostics Market, By Distribution Channel, 2019-2033 (USD Million)
17.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Distribution Channel (2019-2026)
17.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Distribution Channel (2027-2033)
18. Asia Pacific Bladder Cancer Diagnostics Market, By Region, 2019-2033 (USD Million)
18.1. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Region (2019-2026)
18.2. Asia Pacific Bladder Cancer Diagnostics Market Size and Market Share by Region (2027-2033)
18.3. Australia
18.4. China
18.5. India
18.6. Indonesia
18.7. Japan
18.8. Malaysia
18.9. Philippines
18.10. Singapore
18.11. South Korea
18.12. Thailand
18.13. Rest of Asia Pacific
19. Company Profile
19.1. Abbott
19.1.1. Company details
19.1.2. Financial outlook
19.1.3. Product summary
19.1.4. Recent developments
19.2. Agilent Technologies Inc.
19.2.1. Company details
19.2.2. Financial outlook
19.2.3. Product summary
19.2.4. Recent developments
19.3. Ambu A/S
19.3.1. Company details
19.3.2. Financial outlook
19.3.3. Product summary
19.3.4. Recent developments
19.4. Bio-Rad Laboratories Inc.
19.4.1. Company details
19.4.2. Financial outlook
19.4.3. Product summary
19.4.4. Recent developments
19.5. Canon Medical Systems Corporation
19.5.1. Company details
19.5.2. Financial outlook
19.5.3. Product summary
19.5.4. Recent developments
19.6. Cepheid
19.6.1. Company details
19.6.2. Financial outlook
19.6.3. Product summary
19.6.4. Recent developments
19.7. F. Hoffmann-La Roche Ltd
19.7.1. Company details
19.7.2. Financial outlook
19.7.3. Product summary
19.7.4. Recent developments
19.8. Fujifilm Corporation
19.8.1. Company details
19.8.2. Financial outlook
19.8.3. Product summary
19.8.4. Recent developments
19.9. General Electric Company
19.9.1. Company details
19.9.2. Financial outlook
19.9.3. Product summary
19.9.4. Recent developments
19.10. Hologic Inc.
19.10.1. Company details
19.10.2. Financial outlook
19.10.3. Product summary
19.10.4. Recent developments
19.11. Illumina Inc.
19.11.1. Company details
19.11.2. Financial outlook
19.11.3. Product summary
19.11.4. Recent developments
19.12. Koninklijke Philips N.V.
19.12.1. Company details
19.12.2. Financial outlook
19.12.3. Product summary
19.12.4. Recent developments
19.13. Merck KGaA
19.13.1. Company details
19.13.2. Financial outlook
19.13.3. Product summary
19.13.4. Recent developments
19.14. MinFound Medical Systems Co
19.14.1. Company details
19.14.2. Financial outlook
19.14.3. Product summary
19.14.4. Recent developments
19.15. Neusoft Corporation
19.15.1. Company details
19.15.2. Financial outlook
19.15.3. Product summary
19.15.4. Recent developments
19.16. QIAGEN
19.16.1. Company details
19.16.2. Financial outlook
19.16.3. Product summary
19.16.4. Recent developments
19.17. Siemens Healthcare GmbH
19.17.1. Company details
19.17.2. Financial outlook
19.17.3. Product summary
19.17.4. Recent developments
19.18. Thermo Fisher Scientific Inc.
19.18.1. Company details
19.18.2. Financial outlook
19.18.3. Product summary
19.18.4. Recent developments
19.19. Time Medical Holding
19.19.1. Company details
19.19.2. Financial outlook
19.19.3. Product summary
19.19.4. Recent developments
19.20. Others
20. List of Abbreviations
21. Reference Links
22. Conclusion
23. Research Scope